

# Anne M Mills

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3681965/publications.pdf>

Version: 2024-02-01

90  
papers

3,040  
citations

147566

31  
h-index

174990

52  
g-index

91  
all docs

91  
docs citations

91  
times ranked

4450  
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology. American Journal of Surgical Pathology, 2018, 42, 39-52.	2.1	289
2	Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer. American Journal of Surgical Pathology, 2014, 38, 1501-1509.	2.1	208
3	PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages. American Journal of Surgical Pathology, 2017, 41, 334-342.	2.1	143
4	Clinically Relevant Molecular Subtypes in Leiomyosarcoma. Clinical Cancer Research, 2015, 21, 3501-3511.	3.2	129
5	PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. American Journal of Surgical Pathology, 2017, 41, 326-333.	2.1	113
6	A Comparison of CMV Detection in Gastrointestinal Mucosal Biopsies Using Immunohistochemistry and PCR Performed on Formalin-fixed, Paraffin-embedded Tissue. American Journal of Surgical Pathology, 2013, 37, 995-1000.	2.1	108
7	Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms. Modern Pathology, 2019, 32, 1008-1022.	2.9	89
8	HR-HPV E6/E7 mRNA In Situ Hybridization. American Journal of Surgical Pathology, 2017, 41, 607-615.	2.1	87
9	Atypical Leiomyomas of the Uterus. American Journal of Surgical Pathology, 2013, 37, 643-649.	2.1	84
10	Lynch Syndrome Screening in the Gynecologic Tract. American Journal of Surgical Pathology, 2016, 40, e35-e44.	2.1	68
11	IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Modern Pathology, 2018, 31, 1513-1522.	2.9	68
12	Cell Cycle Regulatory Markers in Uterine Atypical Leiomyoma and Leiomyosarcoma. American Journal of Surgical Pathology, 2013, 37, 634-642.	2.1	65
13	Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry. American Journal of Surgical Pathology, 2016, 40, 155-165.	2.1	64
14	The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma. American Journal of Surgical Pathology, 2018, 42, 183-191.	2.1	63
15	Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Modern Pathology, 2017, 30, 1622-1632.	2.9	62
16	Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors. Gynecologic Oncology, 2017, 144, 607-612.	0.6	61
17	Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-positive Subset of Triple-Negative Breast Cancers. American Journal of Surgical Pathology, 2016, 40, 1109-1116.	2.1	58
18	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. Journal of Pathology, 2020, 252, 178-188.	2.1	53

#	ARTICLE	IF	CITATIONS
19	Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer. <i>Theranostics</i> , 2018, 8, 2782-2798.	4.6	51
20	Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1549-1555.	2.1	49
21	Endocervical Fibroblastic Malignant Peripheral Nerve Sheath Tumor (Neurofibrosarcoma). <i>American Journal of Surgical Pathology</i> , 2011, 35, 404-412.	2.1	43
22	PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy. <i>Histopathology</i> , 2019, 74, 256-268.	1.6	42
23	Endometrial hyperplasia. <i>Seminars in Diagnostic Pathology</i> , 2010, 27, 199-214.	1.0	41
24	Diagnostic Efficiency in Digital Pathology. <i>American Journal of Surgical Pathology</i> , 2018, 42, 53-59.	2.1	40
25	Risk Stratification By p16 Immunostaining of CIN1 Biopsies. <i>American Journal of Surgical Pathology</i> , 2015, 39, 611-617.	2.1	39
26	Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. <i>Modern Pathology</i> , 2018, 31, 1282-1290.	2.9	39
27	Predictive Value of Cytokeratin 7 Immunohistochemistry in Cervical Low-grade Squamous Intraepithelial Lesion as a Marker for Risk of Progression to a High-grade Lesion. <i>American Journal of Surgical Pathology</i> , 2016, 40, 236-243.	2.1	37
28	Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1216-1223.	2.1	36
29	Expression of Subtype-Specific Group 1 Leiomyosarcoma Markers in a Wide Variety of Sarcomas by Gene Expression Analysis and Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2011, 35, 583-589.	2.1	35
30	How we treat: risk mitigation for ABO-incompatible plasma in plateletpheresis products. <i>Transfusion</i> , 2012, 52, 2081-2085.	0.8	35
31	Osteogenic tumors of bone. <i>Seminars in Diagnostic Pathology</i> , 2014, 31, 21-29.	1.0	34
32	Malignant Brenner tumor of the ovary: Review and case report. <i>Gynecologic Oncology Reports</i> , 2017, 22, 26-31.	0.3	34
33	Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). <i>International Journal of Gynecological Pathology</i> , 2019, 38, 157-170.	0.9	34
34	PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors. <i>American Journal of Surgical Pathology</i> , 2019, 43, 792-801.	2.1	28
35	Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia. <i>Modern Pathology</i> , 2020, 33, 1182-1192.	2.9	28
36	Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. <i>Gynecologic Oncology</i> , 2017, 146, 34-38.	0.6	27

#	ARTICLE	IF	CITATIONS
37	TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers. <i>Modern Pathology</i> , 2019, 32, 1168-1179.	2.9	27
38	Sclectosing Microcystic Adenocarcinoma of the Head and Neck Mucosa: A Neoplasm Closely Resembling Microcystic Adnexal Carcinoma. <i>Head and Neck Pathology</i> , 2016, 10, 501-508.	1.3	26
39	LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 203-212.	0.9	26
40	Expanding Opportunities for Professional Development: Utilization of Twitter by Early Career Women in Academic Medicine and Science. <i>JMIR Medical Education</i> , 2018, 4, e11140.	1.2	26
41	Are Women With Endocervical Adenocarcinoma at Risk for Lynch Syndrome? Evaluation of 101 Cases Including Unusual Subtypes and Lower Uterine Segment Tumors. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 463-469.	0.9	25
42	Lynch Syndrome. <i>Surgical Pathology Clinics</i> , 2016, 9, 201-214.	0.7	25
43	HPV E6/E7 mRNA In Situ Hybridization in the Diagnosis of Cervical Low-grade Squamous Intraepithelial Lesions (LSIL). <i>American Journal of Surgical Pathology</i> , 2018, 42, 192-200.	2.1	23
44	MHC Class I Loss in Triple-negative Breast Cancer. <i>American Journal of Surgical Pathology</i> , 2021, 45, 701-707.	2.1	23
45	Androgen Receptor Expression in Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 167-173.	0.9	22
46	CK7 Immunohistochemistry as a Predictor of CIN1 Progression. <i>American Journal of Surgical Pathology</i> , 2017, 41, 143-152.	2.1	21
47	Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1184-1191.	2.1	18
48	Mismatch Repair Deficiency in Uterine Carcinosarcoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 782-792.	2.1	18
49	Mesonephric-like Endometrial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 921-932.	2.1	17
50	Mucinous Ovarian Tumors. <i>Surgical Pathology Clinics</i> , 2019, 12, 565-585.	0.7	16
51	Neurofibrosarcoma Revisited. <i>American Journal of Surgical Pathology</i> , 2021, 45, 638-652.	2.1	16
52	Smooth Muscle Tumors of the Female Genital Tract. <i>Surgical Pathology Clinics</i> , 2009, 2, 625-677.	0.7	15
53	Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 558-566.	0.9	15
54	From slide sets to sound bites: teaching and learning pathology in the digital age. <i>Journal of the American Society of Cytopathology</i> , 2014, 3, 183-187.	0.2	14

#	ARTICLE	IF	CITATIONS
55	Mucinous Differentiation With Tumor Infiltrating Lymphocytes Is a Feature of Sporadically Methylated Endometrial Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 205-216.	0.9	13
56	Emerging biomarkers in ovarian granulosa cell tumors. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 560-565.	1.2	13
57	MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition. <i>Modern Pathology</i> , 2021, 34, 627-636.	2.9	13
58	Evaluation of ProExC as a Prognostic Marker in Oropharyngeal Squamous Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1158-1164.	2.1	11
59	Laboratory-Developed L1 Sequencing and Type-Specific, Real-Time Polymerase Chain Reaction for the Detection and Typing of Human Papillomaviruses in Formalin-Fixed, Paraffin-Embedded Tissues. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 50-54.	1.2	11
60	Parasitism as a potential contributor to massive clam mortality at the Blake Ridge Diapir methane-hydrate seep. <i>Journal of the Marine Biological Association of the United Kingdom</i> , 2005, 85, 1489-1497.	0.4	10
61	The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 113-121.	0.9	8
62	Financial Health for the Pathology Trainee: Fiscal Prevention, Diagnosis, and Targeted Therapy for Young Physicians. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 12-15.	1.2	7
63	HPV RNA in situ hybridization can inform cervical cytology&#x2013;histology correlation. <i>Cancer Cytopathology</i> , 2018, 126, 533-540.	1.4	7
64	A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 473-482.	1.1	7
65	Galectin-3 Expression in High-Risk HPV-Positive and Negative Head & Neck Squamous Cell Carcinomas and Regional Lymph Node Metastases. <i>Head and Neck Pathology</i> , 2021, 15, 163-168.	1.3	7
66	Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists. <i>Modern Pathology</i> , 2022, 35, 142-151.	2.9	7
67	Putative precancerous lesions of vulvar squamous cell carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 27-36.	1.0	7
68	$\beta$ -catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 993-999.	1.2	6
69	PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 563-574.	0.9	6
70	Atypical Endometrial Hyperplasia and Well Differentiated Endometrioid Adenocarcinoma of the Uterine Corpus. <i>Surgical Pathology Clinics</i> , 2011, 4, 149-198.	0.7	5
71	Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution&#x2013;s high-risk population. <i>Human Pathology</i> , 2018, 82, 20-31.	1.1	5
72	Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas. <i>Human Pathology</i> , 2018, 82, 282-288.	1.1	5

#	ARTICLE	IF	CITATIONS
73	Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes. <i>Gynecologic Oncology</i> , 2019, 152, 119-126.	0.6	5
74	“What Do You Mean It’s Not Cancer?” A Review of Autoimmune and Systemic Inflammatory Diseases Involving the Breast. <i>Journal of Breast Imaging</i> , 2021, 3, 612-625.	0.5	4
75	PD-L1 Interpretation in Cervical Carcinomas: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 1-4.	0.9	4
76	Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 801764.	1.3	4
77	Extrasosseous Gaucher cell deposition without adjacent bone involvement. <i>Skeletal Radiology</i> , 2014, 43, 1495-1498.	1.2	3
78	p16 Immunohistochemistry Interpretation by Nonpathologists as an Accurate Method for Diagnosing Cervical Precancer and Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 207-211.	0.9	3
79	MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 1-11.	0.9	3
80	Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 8972-8984.	0.8	3
81	PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall. <i>International Journal of Gynecological Pathology</i> , 2022, Publish Ahead of Print, .	0.9	2
82	The pap smear caught it!: Harmonizing the findings of an abnormal pap smear and a right ovarian mass. <i>Diagnostic Cytopathology</i> , 2015, 43, 1039-1041.	0.5	1
83	PD-L1 pitfalls: Emphasizing the importance of membranous localization and correlation with tumor cell and macrophage distributions. <i>Gynecologic Oncology Reports</i> , 2017, 20, 135-136.	0.3	1
84	Endometrial Carcinoma. , 2019, , 455-513.		1
85	Hereditary Endometrial Carcinoma. <i>Molecular Pathology Library</i> , 2017, , 169-186.	0.1	1
86	Malignant Phyllodes Tumor of the Breast: A Case Study. <i>Clinical Journal of Oncology Nursing</i> , 2014, 18, 595-597.	0.3	0
87	Man With Hypoechoic Lesion Abutting the Pancreas. <i>JAMA Surgery</i> , 2014, 149, 393.	2.2	0
88	Human papillomavirus cytopathic effect in the urine of a 76-year-old man. <i>Diagnostic Cytopathology</i> , 2020, 48, 489-490.	0.5	0
89	Cervical Squamous Intraepithelial Lesions. , 2017, , 91-114.		0
90	Epithelial Malignant Tumors of the Cervix: Squamous Carcinoma. , 2021, , 137-167.		0